Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA). [More]

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler. [More]
PET/CT may enhance detection of inflammatory bowel diseases in the future

PET/CT may enhance detection of inflammatory bowel diseases in the future

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine. [More]

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say. [More]
Opinion pieces address World Malaria Day

Opinion pieces address World Malaria Day

On Thursday, the international community recognized World Malaria Day, observed annually on April 25. This year's theme was "Invest in the future. Defeat malaria." [More]
CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause. [More]

Globalpost examines implications of U.S. budget negotiations on global health spending

In the first article in a special report titled "The Seven Million," which looks at "the many challenges faced worldwide in an effort to reduce child mortality" and is "supported through a partnership with the Kaiser Family Foundation," GlobalPost examines the implications of U.S. budget negotiations on global health spending. [More]
Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype. [More]
University of Guelph researchers develop carbohydrate-based vaccine against gut bug

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

A first-ever vaccine created by University of Guelph researchers for gut bacteria common in autistic children may also help control some autism symptoms. [More]
Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types. [More]
Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. [More]
New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013. [More]
ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections. [More]
Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

Older adults represent an important and growing demographic in emergency departments across the country, with urinary tract infections being one of the leading causes for ED visits. [More]
GAPPD presents opportunity to meld global, local agendas

GAPPD presents opportunity to meld global, local agendas

"Beyond integration across the two diseases, the [Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD) released by the WHO and UNICEF last week] is an opportunity to meld global and local agendas, giving national governments a comprehensive tool to determine the specific plans, investments, and partners needed to address the unique needs of their countries and achieve the greatest health impact for their citizens," PATH CEO Steve Davis writes in the Huffington Post's "Global Motherhood" blog. [More]
Study suggests strain with Haiti cholera mutations may increase severity of disease

Study suggests strain with Haiti cholera mutations may increase severity of disease

The cholera strain that transferred to Haiti in 2010 has multiple toxin gene mutations that may account for the severity of disease and is evolving to be more like an 1800s version of cholera, reports a new Northwestern Medicine study. [More]

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema. [More]

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits. [More]

Luminex's MAGPIX instrument gets FDA approval

Luminex Corporation today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel. [More]

Gates Foundation's programs complement new global plan to prevent 2M child deaths

John Grove, a senior program officer at the Bill & Melinda Gates Foundation, and Gretchen Meller, a program officer at the foundation, write in the group's "Impatient Optimists" blog, "By addressing [pneumonia and diarrhea] together, the [Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea] goes to the heart of the matter: both diseases are caused by a range of pathogens, and no single intervention alone will eliminate either disease. [More]